StockData
Damora Therapeutics, Inc. logo

Damora Therapeutics, Inc. (DMRA) stock

DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$22.56+0.06 (+0.29%)

Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%

Damora Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Damora Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $98.11M, up 2048.2% year over year. For fiscal 2025 it was $26.88M, up 320.1% from the year before. The highest annual figure on record is $48.21M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$26.88M+320.1%
FY2024Dec 31, 2024$6.40M-73.1%
FY2023Dec 31, 2023$23.77M-50.7%
FY2022Dec 31, 2022$48.21M+25.2%
FY2021Dec 31, 2021$38.49M+56.3%
FY2020Dec 31, 2020$24.63M+24.8%
FY2019Dec 31, 2019$19.74M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$25.48M+1699.1%
Q2 FY2026Jun 30, 2026$25.54M+1643.3%
Q1 FY2026Mar 31, 2026$23.78M+3406.9%
Q4 FY2025Dec 31, 2025$23.32M+2213.3%
Q3 FY2025Sep 30, 2025$1.42M+29.6%
Q2 FY2025Jun 30, 2025$1.47M-20.1%
Q1 FY2025Mar 31, 2025$678.00K-72.5%
Q4 FY2024Dec 31, 2024$1.01M-63.6%
Q3 FY2024Sep 30, 2024$1.09M-57.2%
Q2 FY2024Jun 30, 2024$1.83M-77.3%
Q1 FY2024Mar 31, 2024$2.46M-76.2%
Q4 FY2023Dec 31, 2023$2.77M-74.3%
Q3 FY2023Sep 30, 2023$2.55M-75.7%
Q2 FY2023Jun 30, 2023$8.09M-41.0%
Q1 FY2023Mar 31, 2023$10.36M-21.7%
Q4 FY2022Dec 31, 2022$10.77M+6.5%
Q3 FY2022Sep 30, 2022$10.49M+7.7%
Q2 FY2022Jun 30, 2022$13.71M+58.7%
Q1 FY2022Mar 31, 2022$13.24M+32.5%
Q4 FY2021Dec 31, 2021$10.12M+30.5%
Q3 FY2021Sep 30, 2021$9.75M+27.4%
Q2 FY2021Jun 30, 2021$8.64M+91.3%
Q1 FY2021Mar 31, 2021$9.99M+112.2%
Q4 FY2020Dec 31, 2020$7.75M-1.2%
Q3 FY2020Sep 30, 2020$7.65M+108.2%
Q2 FY2020Jun 30, 2020$4.52M–
Q1 FY2020Mar 31, 2020$4.71M–
Q4 FY2019Dec 31, 2019$7.85M–
Q3 FY2019Sep 30, 2019$3.67M–

More Damora Therapeutics figures

See a number that looks wrong?